Gibson Christopher sold $145K of RXRX
Gibson Christopher sold 40,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.62 ($0.14M total) on 2026-06-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on insider liquidity and potential sentiment, but the presence of a 10b5-1 plan limits inference about new information.
Market read
A director’s 10b5-1 sale is typically not a standalone fundamental catalyst; expect muted price reaction unless paired with other negative news.
What to watch
Traders may over-weight single insider trades; without additional context (e.g., multiple concurrent sales or changes in buying), signal quality is low.
Background
The article is an SEC Form 4 insider transaction disclosure for Recursion Pharmaceuticals (RXRX).
Ticker impact
Recursion Pharmaceuticals director Gibson Christopher sold 40,000 shares in an open-market transaction disclosed on SEC Form 4.
Likely limited near-term impact; any move would be small and sentiment-driven rather than catalyst-driven.
The transaction is disclosed with a Rule 10b5-1 pre-arranged plan, which typically dampens inference about new negative information.
Market effects
Minimal; this is company-specific insider activity with no stated sector-wide development.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations.
Key entities
- issuerRecursion Pharmaceuticals, Inc.
Subject of the SEC Form 4 insider sale by a director.
- insiderGibson Christopher
Director who sold 40,000 shares at $3.6200/share under a pre-arranged 10b5-1 plan.
